Condition: Acute Myeloid Leukemia · Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
The standard treatment for patients with acute myeloid leukemia (AML) with an abnormality in the IDH1 gene, who are not eligible for intensive chemotherapy, is a combination of ivosidenib and azacitidine. In this study it is investigated whether adding venetoclax to the standard treatment can improve the outcome of the treatment of this specific form of AML. The safety is investigated and how well it works. In order to properly assess the value of venetoclax, the effect of venetoclax is compared with the effect of a placebo. A placebo is a product without an active ingredient, a 'fake medicinal product'.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| AT-Feldkirch-IKHF | Feldkirch, Austria | Not Yet Recruiting |
| AT-Salzburg-SALK | Salzburg, Austria | Not Yet Recruiting |
| AT-Vienna-HANUSCH | Vienna, Austria | Not Yet Recruiting |
| BE-Antwerpen-ZAS | Antwerp, Belgium | Not Yet Recruiting |
| BE-Brussel-BORDET | Brussels, Belgium | Not Yet Recruiting |
| BE-Brussel-UZBRUSSEL | Brussels, Belgium | Not Yet Recruiting |
| BE-Bruxelles-STLUC | Brussels, Belgium | Not Yet Recruiting |
| BE-Gent-UZGENT | Ghent, Belgium | Not Yet Recruiting |
| BE-Leuven-UZLEUVEN | Leuven, Belgium | Not Yet Recruiting |
| BE-Liege-CHULIEGE | Liège, Belgium | Not Yet Recruiting |
| BE-Yvoir-MONTGODINNE | Yvoir, Belgium | Recruiting |
| DK-Aalborg-AALBORGUH | Aalborg, Denmark | Not Yet Recruiting |
+ 107 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07075016